Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease
- 1 July 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 22 (7), 1382-1389
- https://doi.org/10.1681/asn.2010111185
Abstract
Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD. Furthermore, because arterial stiffness increases left ventricular afterload, any allopurinol-induced improvement in arterial compliance might also regress left ventricular hypertrophy (LVH). We conducted a randomized, double-blind, placebo-controlled, parallel-group study in patients with stage 3 CKD and LVH. We randomly assigned 67 subjects to allopurinol at 300 mg/d or placebo for 9 months; 53 patients completed the study. We measured left ventricular mass index (LVMI) with cardiac magnetic resonance imaging (MRI), assessed endothelial function by flow-mediated dilation (FMD) of the brachial artery, and evaluated central arterial stiffness by pulse-wave analysis. Allopurinol significantly reduced LVH (P = 0.036), improved endothelial function (P = 0.009), and improved the central augmentation index (P = 0.015). This study demonstrates that allopurinol can regress left ventricular mass and improve endothelial function among patients with CKD. Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.Keywords
This publication has 31 references indexed in Scilit:
- Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular RiskClinical Journal of the American Society of Nephrology, 2010
- Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular massHeart, 2009
- Association between allopurinol and mortality in heart failure patients: a long-term follow-up studyInternational Journal of Clinical Practice, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Xanthine Oxidase Inhibition With Febuxostat Attenuates Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction in MiceJournal of Cardiac Failure, 2008
- Left Ventricular Hypertrophy Reversal and Prevention of DiabetesHypertension, 2007
- Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imagingKidney International, 2006
- Xanthine Oxidase Inhibition With Oxypurinol Improves Endothelial Vasodilator Function in Hypercholesterolemic but Not in Hypertensive PatientsHypertension, 1997
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989